Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | SCD | O00767 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.41 |
| ▸ | CNR2 | P34972 | 11/20 | 0.40 |
| ▸ | CNR1 | P21554 | 8/20 | 0.40 |
| ▸ | RAF1 | P04049 | 1/20 | 0.37 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2185599 | 0.86 | CNR2 (0.51) | ALDH1A1SCDMAPK14CNR2CNR1 | |
| SCHEMBL2186137 | 0.80 | CNR2 (0.43) | ALDH1A1SCDMAPK14CNR2CNR1 | |
| SCHEMBL13391436 | 0.78 | ALDH1A1 (0.47) | ALDH1A1SCDMAPK14CNR2CNR1 | |
| SCHEMBL5319788 | 0.76 | ALDH1A1 (0.54) | ALDH1A1SCD | |
| SCHEMBL3136764 | 0.75 | CNR2 (0.46) | ALDH1A1SCDCNR2CNR1 | |
| SCHEMBL892659 | 0.75 | SCD (0.53) | ALDH1A1SCDMAPK14CYP17A1 | |
| SCHEMBL24959797 | 0.73 | SCD (0.44) | ALDH1A1SCDCYP17A1 | |
| SCHEMBL892677 | 0.72 | SCD (0.48) | ALDH1A1SCD | |
| SCHEMBL11732172 | 0.71 | ALDH1A1 (0.67) | ALDH1A1MAPK14CNR2CNR1RAF1 | |
| SCHEMBL18844573 | 0.70 | MEN1 (0.46) | SCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2342199-B1 | Sulfonyl compounds which selectively modulate the CB2 receptor | BOEHRINGER INGELHEIM INT (DE) | 2014-02-26 | — | — | EP | disclosed |
| US-8372874-B2 | Compounds which selectively modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-12 | — | — | US | disclosed |
| US-8372874-B2 | Compounds which selectively modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-12 | — | — | US | disclosed |
| US-8372874-B2 | Compounds which selectively modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-12 | — | — | US | disclosed |
| EP-2342199-A2 | COMPOUNDS WHICH SELECTIVELY MODULATE THE CB2 RECEPTOR | Boehringer Ingelheim International GmbH (DE) | 2011-07-13 | — | — | EP | disclosed |
| WO-2010036631-A2 | COMPOUNDS WHICH SELECTIVELY MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | WO | disclosed |
| WO-2010036631-A2 | COMPOUNDS WHICH SELECTIVELY MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | WO | disclosed |
| US-20100076029-A1 | Compounds Which Selectively Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-25 | — | — | US | disclosed |
| US-20100076029-A1 | Compounds Which Selectively Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-25 | — | — | US | disclosed |
| US-20100076029-A1 | Compounds Which Selectively Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076029-A1 | Compounds Which Selectively Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | ALDH1A1 2112/4885SCD 1678/4885MAPK14 1381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.